Company Profile
Twist Bioscience Corporation Stock Price, News & Analysis
- Ticker:
- TWST
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
109.08 USD (-5.16%)
Close
Last updated: August 6, 2026
4.37B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TWST closed down 5.16% at $109.08. No new same-company headline was identified in the current news window.
Company overview
Synthetic Biology Platform
Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows.
Oligos and Genes
Core products include oligonucleotides, genes and complex DNA constructs used by researchers to build, test and optimize biological designs across large experimental programs.
Next-Generation Sequencing
Twist supplies target-enrichment panels and workflow tools for next-generation sequencing in research, diagnostics and translational medicine.
Biopharma Solutions
The company provides antibody-discovery libraries, protein products and characterization data that help biotechnology and pharmaceutical customers identify and optimize therapeutic candidates.
Broad End Markets
Twist serves customers in therapeutics, diagnostics, industrial biotechnology, agriculture and academic research, applying the same manufacturing platform across diverse biological applications.
Future catalysts
Twist Bioscience's catalysts are synthetic-DNA demand, sequencing-library usage, and whether biopharma spending keeps improving. The company improves if the tools market keeps showing healthier demand.
Recent news
- 01
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Source: Twist Bioscience Corporation
- 02
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Source: Twist Bioscience Corporation
- 03
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Source: Twist Bioscience Corporation
- 04
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
Source: Twist Bioscience Corporation
- 05
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
Source: Twist Bioscience Corporation
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Twist Bioscience Corporation (TWST)?
Twist Bioscience Corporation (TWST) most recently closed at 109.08 USD, a -5.16% move versus the previous session.
What is the market cap of Twist Bioscience Corporation (TWST)?
Twist Bioscience Corporation currently has a market capitalization of 4.37B USD on BioPharmSignal.
What does Twist Bioscience Corporation do?
Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by researchers to build,...
On which exchange is TWST stock listed?
Twist Bioscience Corporation (TWST) is associated with NASDAQ, United States, Biopharma.
What is Synthetic?
Twist Bioscience's catalysts are synthetic-DNA demand, sequencing-library usage, and whether biopharma spending keeps improving.
Which conditions is Twist Bioscience Corporation targeting with Synthetic?
Twist Bioscience's catalysts are synthetic-DNA demand, sequencing-library usage, and whether biopharma spending keeps improving.
How does Twist Bioscience Corporation describe recent progress with Synthetic?
Twist Bioscience's catalysts are synthetic-DNA demand, sequencing-library usage, and whether biopharma spending keeps improving.
What is Biology?
Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale.